A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Pain Attributed to Osteoarthritis of the Knee
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2018
At a glance
- Drugs LEVI 04 (Primary)
- Indications Pain
- Focus Adverse reactions; First in man
- Sponsors Levicept
- 26 Sep 2018 Planned End Date changed from 1 Apr 2019 to 1 Oct 2019.
- 26 Sep 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Oct 2019.
- 31 Aug 2018 Biomarkers information updated